Browse Category

Stock Market News 29 December 2025

Oracle stock slips after insider sale filing as OpenAI-linked spending stays in focus

Oracle stock slips after insider sale filing as OpenAI-linked spending stays in focus

NEW YORK, December 29, 2025, 09:56 ET — Regular session Oracle shares fell 0.4% to $197.27 in early trading on Monday after a company officer disclosed a planned share sale, with investors still wary about the cost of the software maker’s push to expand AI-related cloud capacity. The filing matters because Oracle has become a touchstone for a broader market…
AMD slips as tech rally pauses; Nvidia-Intel filing puts chip sector back in focus

AMD slips as tech rally pauses; Nvidia-Intel filing puts chip sector back in focus

NEW YORK, December 29, 2025, 09:54 ET — Regular session Advanced Micro Devices shares edged lower in early trading on Monday, dipping 0.3% to $214.42 after touching an intraday low of $209.42. The move mattered because the market is entering the final, holiday-thinned stretch of the year, when small shifts in risk appetite can swing high-growth technology names. Semiconductor stocks…
Microsoft stock dips as Wall Street’s year-end rally pauses, Fed minutes loom

Microsoft stock dips as Wall Street’s year-end rally pauses, Fed minutes loom

NEW YORK, December 29, 2025, 09:49 ET — Regular session Microsoft (MSFT.O) shares were down 0.3% at $486.46 in early trading on Monday. The pullback came as Wall Street’s year-end rally cooled in holiday-thinned conditions, with heavyweight technology stocks giving up some of last week’s gains. Reuters Investors are looking to the Federal Reserve’s meeting minutes on Tuesday — a…
Palantir slips as Karp’s paid “college alternative” hits headlines in weak year-end trade

Palantir slips as Karp’s paid “college alternative” hits headlines in weak year-end trade

NEW YORK, December 29, 2025, 09:46 ET — Regular session Palantir Technologies Inc shares were down 0.9% at $187.10 shortly after the opening bell on Monday, reversing a small early bounce as the broader tech sector softened. The move matters because Palantir is one of the market’s biggest momentum names into year-end, leaving the stock sensitive to headlines and risk-off…
Broadcom stock falls at the open as year-end rally cools and AI margin worries linger

Broadcom stock falls at the open as year-end rally cools and AI margin worries linger

NEW YORK, December 29, 2025, 09:39 ET — Regular session Broadcom shares fell about 1.4% to $347.37 in early New York trading on Monday, underperforming a softer tech sector as investors turned cautious in the final week of 2025. Investing The move matters now because Broadcom sits in the middle of the market’s crowded “AI infrastructure” trade, where investors have…
Apple stock slips early as year-end tech rally cools, with China demand in focus

Apple stock slips early as year-end tech rally cools, with China demand in focus

NEW YORK, December 29, 2025, 09:41 ET — Regular session Apple shares edged lower in early New York trading on Monday, slipping about 0.2% to $273.40. The pullback comes as heavyweight technology stocks give back some ground after last week’s gains pushed the S&P 500 to fresh highs and left it within about 1% of the 7,000 mark, Reuters reported.…
Nvidia stock slips as Intel filing confirms $5 billion stake — here’s what’s next

Nvidia stock slips as Intel filing confirms $5 billion stake — here’s what’s next

NEW YORK, December 29, 2025, 09:35 ET — Regular session Nvidia shares were down about 1.4% at $187.92 in early U.S. trading on Monday after Intel disclosed details of a $5 billion share sale to the AI chipmaker. MarketScreener The disclosure matters now because it confirms the cash outlay and turns a headline September agreement into an executed equity stake,…
Firefly Aerospace stock steadies in premarket as lawsuit notice puts spotlight back on IPO claims

Firefly Aerospace stock steadies in premarket as lawsuit notice puts spotlight back on IPO claims

NEW YORK, December 29, 2025, 08:00 ET — Premarket Firefly Aerospace Inc shares edged down 0.1% to $23.34 in premarket trading on Monday. The muted move keeps attention on the recently listed space-and-defense company as legal headlines circulate into the final, holiday-thinned week of the year, when smaller stocks can swing on limited volume. PR Newswire U.S. stock index futures…
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

NEW YORK, December 29, 2025, 09:43 ET — Regular session Tesla shares fell about 2.2% to $464.88 in early trade on Monday, after South Korea’s L&F said the value of a battery-material supply deal with Tesla had shrunk to just $7,386 from an earlier projection of $2.9 billion. Google The revision landed as investors scrutinize whether Tesla’s in-house “4680” battery…
Micron stock slips on ex-dividend day as chip rally cools into year-end

Micron stock slips on ex-dividend day as chip rally cools into year-end

NEW YORK, December 29, 2025, 09:41 ET — Regular session Micron Technology (MU.O) shares fell 0.6% to $284.79 in early trade on Monday. The move mattered for two reasons: Micron started trading ex-dividend, and the broader tech bid that powered last week’s gains cooled into the final week of 2025. Nasdaq An ex-dividend date is the cutoff that determines who…
Nvidia’s $5B Intel stake hits the tape as U.S. futures cool into year-end week

Nvidia’s $5B Intel stake hits the tape as U.S. futures cool into year-end week

NEW YORK, December 29, 2025, 08:21 ET U.S. stock index futures slipped on Monday as Nvidia completed a $5 billion purchase of Intel shares, adding a fresh headline to a year-end rally led by technology and AI-linked stocks. Intel disclosed the transaction in a filing on Monday (source). Reuters The move lands as markets head into the final, holiday-shortened trading…

Stock Market Today

  • Pfizer Q4 Preview: Non-Oncology Segment Sales Outlook and Market Impact
    January 19, 2026, 11:10 AM EST. Pfizer (PFE) is scheduled to report Q4 and full-year 2025 earnings on Feb. 3. While oncology sales account for over 28% of revenues, investor focus also shifts to non-oncology segments including Primary Care and Specialty Care. Key non-oncology products include Eliquis anticoagulant, Prevnar vaccines, COVID-19 vaccine Comirnaty, and newer drugs like RSV vaccine Abrysvo and migraine treatment Nurtec. Eliquis alliance revenues are expected to rise to $2.1 billion despite generic pressures. Prevnar vaccine sales likely declined in the U.S. but increased internationally, estimated at $1.64 billion. COVID-19 medication sales fell due to narrower vaccine recommendations and lower infections. In Specialty Care, Vyndaqel sales remain strong at an estimated $1.66 billion, while Xeljanz and Enbrel may have weakened. Pfizer's stock dropped 2.5% in past year, underperforming the industry, but trades at a forward price/earnings ratio of 8.58, suggesting valuation appeal.
Go toTop